HotPennyStockNews.com is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
Los Angelas, CA -- (SBWIRE) -- 09/18/2012 -- Renewable Energy (NGM:REGI) reported EPS of 3.145. For the Current Fiscal year, the company is expected to report EPS of 0.71. For the Next Quarter and Next Year, the company is expected to report EPS of 0.14 and 1.14 respectively. At Current Market Price, REGI is in distance of +50.69% from its 50-day Moving Average price of $5.4814 and +9.31% from its 200-day Moving Average price of $7.5566. Renewable Energy Group, Inc. (NASDAQ:REGI): According to Piper Jaffray, the EPA’s final approval for the Renewable Fuel Standard II biodiesel volume mandate for 2013 of 1.28 billion gallons, a 1 billion gallon increase in 2012, is a positive for Renewable Energy. Piper keeps its Overweight rating on the stock.
Can REGI Continue to Rise And Make Target Of $ 11? Find Out Here
Royale Energy, In (NCM:ROYL) is very active today and traded between $2.8601 - 3.87 with total traded volume of 1060179 shares. At a current price of 3.76, ROYLis +0.82 - +27.89% from the previous close of $2.94. Moreover, At Current Market Price, ROYL is in distance of +50.62% from its 50-day Moving Average price of $2.4963 and +4.33% from its 200-day Moving Average price of $3.6041.
Get Free Trend Analysis on ROYL: Click Here
BioSante Pharmace (NGM:BPAX) reported EPS of -1.963. For the Current Fiscal year, the company is expected to report EPS of -1.63. For the Next Quarter and Next Year, the company is expected to report EPS of -0.35 and -1.04 respectively. At Current Market Price, BPAX is in distance of +29.17% from its 50-day Moving Average price of $1.4477 and -29.61% from its 200-day Moving Average price of $2.6568. Shares of BioSante Pharmaceuticals Inc. (NASDAQ: BPAX), a specialty pharmaceutical company engaged in the development of products for female sexual health and oncology, saw a huge rally on Monday. Earlier this month, BPAXhad announced that a safety study of LibiGel did not reveal links to heart attack or breast cancer. LibiGel is BPAX’s female sexual dysfunction drug. BPAXalso said earlier this month that it is planning two new trials of LibiGel even though the drug has failed in two late-stage trials.
Get Free Trend Analysis on BPAX: Click Here
Rosetta Genomics (NCM:ROSG) is very active today and traded between $5.42 - 6.22 with total traded volume of 3256986 shares. At a current price of 6.20, ROSG is +0.92 - +17.42% from the previous close of $5.28. Moreover, At Current Market Price, ROSG is in distance of +15.40% from its 50-day Moving Average price of $5.3726 and -9.80% from its 200-day Moving Average price of $6.8735. Shares of Rosetta Genomics Ltd. (NASDAQ:ROSG) popped Monday on word of its plans to release a business update through a conference call on October 2nd, just days prior to its annual meeting set for October 5th. Rosetta has jumped 56 percent over the past 30 days and 130 percent thus far in 2012.
Get Free Trend Analysis on ROSG: Click Here
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)